TipRanks
Go Ultimate55% OFF

Becton Dickinson (BDX) AI Stock Analysis

MX:BDX

Becton Dickinson

(BMV:BDX)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Recurring healthcare demandBD’s large consumables base supports repeat purchasing because needles, catheters, specimen products, reagents, and related supplies are embedded in routine care. This recurring model can provide durable revenue visibility and customer stickiness across healthcare settings.
Negative Factors
Recent earnings deteriorationThe recent contraction in revenue and net margin shows that BD’s otherwise stable operating model is not currently translating into consistent bottom-line growth. If the weaker demand, mix, or cost trends persist, they could constrain earnings quality and internal funding capacity.

Becton Dickinson (BDX) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%MX:BDX+38.85%SPY+13.13%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
MXN 53.90B
Dividend Yield
1.65%
Average Volume (3M)
12
Price to Earnings (P/E)
59.6
Beta (1Y)
0.15
Revenue Growth
-11.05%
EPS Growth
-44.33%
Country
Mexico
Employees
72,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

Becton Dickinson Business Overview & Revenue Model

Company Description

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, a...

Becton Dickinson Earnings Call Summary

Earnings Call Date:Aug 05, 2026(Q3-2026)|% Change Since:35.28%|Next Earnings Date:Nov 04, 2026
Earnings Call SentimentPositive

The call conveyed strong execution across BD's focused med‑tech portfolio: revenue and adjusted EPS beat expectations, growth platforms showed double-digit expansion, productivity and cash flow improved materially, and the company raised EPS guidance. Headwinds are defined and manageable — chiefly Alaris remediation, tariffs, vaccine weakness in China and some margin pressure versus the prior year — and management laid out clear mitigation actions (pricing, productivity, commercial investments, AI for supply chain). Overall the positives materially outweigh the negatives.

Positive Updates

Revenue Outperformance
Q3 revenue of $5.0 billion, up 4.4% year-over-year (FX-neutral), ahead of expectations and driving an update to full-year revenue guidance toward the high end of the low single-digit range.

Negative Updates

Margin Pressure Versus Prior Year
Adjusted gross margin was 54.3% (down ~100 basis points year-over-year) and adjusted operating margin 24.9% (down ~130 basis points year-over-year), with benefits from productivity and mix largely offset by tariffs and investments.

Company Guidance

BD updated fiscal '26 guidance, saying revenue is now expected toward the high end of its low single‑digit FX‑neutral range (currency now a ~100 bp tailwind at current spot rates) and raising the midpoint of adjusted EPS guidance to a range of $12.62–$12.72; the company still expects adjusted operating margin of about 25% (inclusive of tariffs) and an adjusted effective tax rate of 16–17%. Management cited Q3 results of $5.0B revenue (up 4.4%), adjusted gross margin of 54.3%, adjusted operating margin of 24.9% and adjusted EPS of $3.23 as the basis for the update, noted tariffs trimmed margins by roughly 110 bps, and highlighted YTD free cash flow of $1.7B (up 45%) and $3.1B returned to shareholders ($2.3B repurchases, $0.9B dividends) with net leverage ~2.9x (2.5x target). Looking to FY‑27, management reiterated a low single‑digit revenue starting point with a defined ~200 bp Alaris headwind next year and said it expects only “modest” EPS leverage off that baseline, with pricing, BD Excellence productivity and favorable mix helping to offset headwinds and a longer‑term free cash flow conversion goal of ~90%.

Becton Dickinson Risk Analysis

Becton Dickinson disclosed 25 risk factors in its most recent earnings report. Becton Dickinson reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Becton Dickinson Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

MX:BDX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
WSTWST78Outperform$28.74B46.0021.08%0.21%12.60%32.05%
MDLNMDLN69Neutral$42.23B37.355.45%―12.12%-46.11%
ICUIICUI65Neutral$4.10B136.481.41%―-8.84%―
TFXTFX55Neutral$5.92B-6.00-31.83%0.97%-14.49%-644.98%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BAXBAX45Neutral$11.90B-16.67-11.62%0.17%5.33%-164.67%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%MX:BDXBAXICUITFXWSTMDLNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
MX:BDX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
MX:BDXBecton, Dickinson and Co3610.001009.9838.85%
BAXBaxter International Inc23.005.0928.46%
ICUIICU Medical163.7838.1230.34%
TFXTeleflex139.7716.7313.60%
WSTWest Pharmaceutical Services, Inc.412.62126.5744.25%
MDLNMedline, Inc. Class A32.12-8.88-21.66%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.